Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Completed · Phase 3

Conditions studied: Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)

In brief

This study is designed to provide evidence of efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.

Key facts

Study ID

NCT02714595

Run by

Shionogi

People needed

152

Starts

2016-09-07

Expected to finish

2019-04-22

Last updated by the study team

2021-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with clinically documented infection (HAP/VAP/HCAP, cUTI, or BSI/sepsis) caused by a Gram-negative pathogen with evidence of carbapenem resistance
• Patients who have been treated previously with an empiric antibiotic regiment and failed treatment, both clinically and microbiologically, are eligible for the study, if they have an identified carbapenem-resistant Gram-negative pathogen which has either been shown to be nonsusceptible in vitro to each of the antibiotic(s) of the empiric antibiotic regimen or been grown from a culture performed after at least 2 days of the empiric antibiotic regimen
• Patient is male (no contraception required) or female and meets one of the following criteria:
• Surgically sterile by hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy or tubal ligation for the purpose of contraception for at least 6 weeks with appropriate documentation of such surgery
• Postmenopausal (defined as older than 45 years of age with cessation of regular menstrual periods for 6 months and confirmed by a follicle-stimulating hormone level of > 40 mIU/mL, or amenorrhea for at least 12 months)
• Of childbearing potential and using combined (estrogen and progestogen) or progestogen-only hormonal contraception associated with inhibition of ovulation (including oral, intravaginal, injectable, implantable, and transdermal contraceptives), or an intrauterine device (IUD), or intrauterine hormone-releasing system (IUS) for the entire duration of the study
• Of childbearing potential and practice abstinence as a preferred and usual lifestyle, and agrees to continue practicing abstinence from Screening and for the entire duration of the study
• Of childbearing potential, whose sole heterosexual partner has been successfully vasectomized and agrees to not have other heterosexual partners for the entire duration of the study
• Patients meeting specific criteria for each infection site

You may not qualify if…

• Patients who have a history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam (Note: for β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment)
• Patients who need more than 3 systemic antibiotics as part of best available therapy (BAT) for the treatment of the Gram-negative infection (patients with mixed Gram-positive or anaerobic infections may receive appropriate concomitant narrow spectrum antibiotics [eg, vancomycin, linezolid, metronidazole, clindamycin])
• Patients with coinfection caused by invasive aspergillosis, mucormycosis or other highly lethal mold
• Patients who have central nervous system (CNS) infection (eg, meningitis, brain abscess, shunt infection)
• Patients with infection requiring > 3 weeks of antibiotic treatment (eg, bone and joint infection, endocarditis)
• Patients with cystic fibrosis or moderate to severe bronchiectasis
• Patients in refractory septic shock defined as persistent hypotension despite adequate fluid resuscitation or despite vasopressive therapy at the time of Randomization
• Patients with severe neutropenia, ie, polymorphonuclear neutrophils (PMNs) < 100 cells/μL
• Female patients who have a positive pregnancy test at Screening or who are lactating
• Patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) score > 30
• Patients who have received a potentially effective antibiotic regimen for the carbapenem-resistant Gram-negative infection for a continuous duration of more than 24 hours in cUTI, or 36 hours in HAP/VAP/HCAP or BSI/sepsis during the 72 hours leading to Randomization
• Patients with any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the study data
• Patients who have received another investigational drug or device within 30 days prior to study entry
• Patients who have previously been randomized in this study or received S-649266
• Patients receiving peritoneal dialysis
• Patients meeting specific exclusion criteria for each infection site

Where it is running

• Shionogi Research Site — Newark, Delaware, United States
• Shionogi Research Site — Chicago, Illinois, United States
• Shionogi Research Site — New Orleans, Louisiana, United States
• Shionogi Research Site — Detroit, Michigan, United States
• Shionogi Research Site — Pittsburgh, Pennsylvania, United States
• Shionogi Research Site — Salvador, Estado de Bahia, Brazil
• Shionogi Research Site — Curitiba, Paraná, Brazil
• Shionogi Research Site — Passo Fundo, Rio Grande do Sul, Brazil
• Shionogi Research Site — Porto Alegre, Rio Grande do Sul, Brazil
• Shionogi Research Site — Porto Alegre, Rio Grande do Sul, Brazil
• Shionogi Research Site — Santa Maria, Rio Grande do Sul, Brazil
• Shionogi Research Site — São José do Rio Preto, São Paulo, Brazil
• Shionogi Research Site — São Paulo, São Paulo, Brazil
• Shionogi Research Site — Rijeka, Primorje-Gorski Kotar County, Croatia
• Shionogi Research Site — Split, Croatia
• Shionogi Research Site — Zagreb, Croatia
• Shionogi Research Site — La Tronche, Auvergne-Rhône-Alpes, France
• Shionogi Research Site — Paris, Île-de-France Region, France
• Shionogi Research Site — Heidelberg, Baden-Wurttemberg, Germany
• Shionogi Research Site — Bonn, North Rhine-Westphalia, Germany
• Shionogi Research Site — Berlin, Germany
• Shionogi Research Site — Athens, Attica, Greece
• Shionogi Research Site — Athens, Attica, Greece
• Shionogi Research Site — Patra, Peloponnese, Greece
• Shionogi Research Site — Hartford, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.